Home › Gilead Announces Results from Phase 2 Study Showing Reduction in...
 

Keywords :   


Gilead Announces Results from Phase 2 Study Showing Reduction in...

2014-05-11 00:54:46| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden in patients with paroxysmal atrial fibrillation .

Tags: in results showing study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »